Hypersensitivity to daunorubicin or any other component of the product, other anthracyclines, or anthracenediones.
Persistent myelosuppression.
Presence of severe infections.
Severe hepatic (Child-Pugh Grade C [total score 10-15]) or renal function impairment (GFR <10 mL/min or serum creatinine >7.9 mg/dL).
Myocardial insufficiency.
Recent myocardial infarction.
Severe arrhythmias.
Previous treatments with maximum cumulative doses of daunorubicin, other anthracyclines and/or anthracenediones (see Precautions).